Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: Evolution and current status

Brain Pathology

Volumn 23, Issue 6, 2013, Pages 647-660

  Sato, Douglas Kazutoshi ^a   Lana Peixoto, Marco Aurelio ^b   Fujihara, Kazuo ^a   De Seze, Jerome ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

aquaporin 4 antibody; clinical spectrum; neuromyelitis optica; treatment

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB;

ASTROCYTE; AUTOIMMUNE DISEASE; BRAIN DISEASE; BRAIN RADIOGRAPHY; CEREBROSPINAL FLUID; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; ETHNICITY; EVOKED VISUAL RESPONSE; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LABORATORY TEST; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGY; NEUROOPHTHALMOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; ORBIT; POPULATION; PREGNANCY; RELAPSE; SERODIAGNOSIS; SKULL RADIOGRAPHY; SPINAL CORD; VISUAL FIELD;

AQUAPORIN-4 ANTIBODY; CLINICAL SPECTRUM; NEUROMYELITIS OPTICA; TREATMENT;

ADULT; AQUAPORIN 4; BRAIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; NEUROMYELITIS OPTICA;

EID: 84885653434     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12087     Document Type: Conference Paper

References (137)

1. Adoni T, Lino AM, da Gama PD, Apostolos-Pereira SL, Marchiori PE, Kok F, Callegaro D, (2010) Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler 16: 81-86.
2. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA, et al (2010) Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 68: 757-761.
3. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T, (2013) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23: 827-831.
4. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO, (2011) A population-based study of neuromyelitis optica in Caucasians. Neurology 76: 1589-1595.
5. Asgari N, Nielsen C, Stenager E, Kyvik KO, Lillevang ST, (2012) HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. Mult Scler 18: 23-30.
6. Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura T, Gold R, (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70: 394-397.
7. Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD, (2012) Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 18: 108-112.
8. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA, (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17: 1225-1230.
9. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA, (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67: 1131-1136.
10. Bichuetti DB, Oliveira EM, Boulos Fde C, Gabbai AA, (2012) Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 69: 938-939.
11. Birnbaum J, Kerr D, (2008) Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 4: 381-386.
12. Bourre B, Marignier R, Zephir H, Papeix C, Brassat D, Castelnovo G, et al (2012) Neuromyelitis optica and pregnancy. Neurology 78: 875-879.
13. Bouyon M, Collongues N, Zephir H, Ballonzoli L, Jeanjean L, Lebrun C, et al (2013) Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler (Epub February 14, 2013). doi: 10.1177/1352458513476562.
14. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66: 630-643.
15. Brum DG, Barreira AA, dos Santos AC, Kaimen-Maciel DR, Matiello M, Costa RM, et al (2010) HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 16: 21-29.
16. Brum DG, Luizon MR, Santos AC, Lana-Peixoto MA, Rocha CF, Brito ML, et al (2013) European ancestry predominates in neuromyelitis optica and multiple sclerosis patients from Brazil. PLoS ONE 8: e58925.
17. Brusaferri F, Candelise L, (2000) Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 247: 435-442.
18. Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, et al (2001) MS and neuromyelitis optica in Martinique (French West Indies). Neurology 56: 507-514.
19. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D, (2013) Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 84: 511-516.
20. Cabrera-Gomez JA, Kister I, (2012) Conventional brain MRI in neuromyelitis optica. Eur J Neurol 19: 812-819.
21. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R, (2009) An epidemiological study of neuromyelitis optica in Cuba. J Neurol 256: 35-44.
22. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108: 3701-3706.
23. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A, (2011) Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 76: 294-300.
24. Costa RM, Santos AC, Costa LS, (2007) An unusual chiasmal visual defect in a patient with neuromyelitis optica: case report. Arq Bras Oftalmol 70: 153-155.
25. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77: 659-666.
26. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59: 963-969.
27. de Seze J, Blanc F, Jeanjean L, Zephir H, Labauge P, Bouyon M, et al (2008) Optical coherence tomography in neuromyelitis optica. Arch Neurol 65: 920-923.
28. Devic E, (1894) Myelite subaiguë compliquée de névrite optique. Bull Med 8: 1033-1034.
29. Elsone L, Townsend T, Mutch K, Das K, Boggild M, Nurmikko T, Jacob A, (2013) Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler 19: 475-479.
30. Fernandes DB, Ramos Rde I, Falcochio C, Apostolos-Pereira S, Callegaro D, Monteiro ML, (2012) Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 32: 102-106.
31. Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, Nano-Schiavi ML, et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113: 324-332.
32. Fujihara K, Leite MI, (2013) Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges. Neurology 80: 2176-2177.
33. Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, Lassmann H, et al (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58-73.
34. Gault F, (1894) De la neuromyélite optique aiguë. In: Thèsis Lyon.
35. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ, (2012) Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 135: 1786-1793.
36. Gold R, Buttgereit F, Toyka KV, (2001) Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117: 1-8.
37. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW, (2003) The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61: 1332-1338.
38. Green AJ, Cree BA, (2009) Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 80: 1002-1005.
39. Iorio R, Lucchinetti CF, Lennon VA, Costanzi C, Hinson S, Weinshenker BG, Pittock SJ, (2011) Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology 77: 1644-1646.
40. Isobe N, Matsushita T, Yamasaki R, Ramagopalan SV, Kawano Y, Nishimura Y, et al (2010) Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Mult Scler 16: 147-155.
41. Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S, (2009) "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 66: 425-428.
42. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65: 1443-1448.
43. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66: 1128-1133.
44. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131: 3072-3080.
45. Jarius S, Paul F, Franciotta D, de Seze J, Munch C, Salvetti M, et al (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18: 1135-1143.
46. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9: 14.
47. Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, et al (2013) Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260: 627-634.
48. Kanamori Y, Nakashima I, Takai Y, Nishiyama S, Kuroda H, Takahashi T, et al (2011) Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 77: 652-658.
49. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG, (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58: 143-146.
50. Keller AJ, Urbaniak SJ, (1978) Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol 38: 531-540.
51. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ, (2011) Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler 17: 1527-1530.
52. Kidd D, Burton B, Plant GT, Graham EM, (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126: 276-284.
53. Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al (2012) Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70: 390-393.
54. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ, (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68: 1412-1420.
55. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ, (2011) Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68: 473-479.
56. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW, (2012) Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 69: 1026-1031.
57. Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, et al (2010) Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 16: 1229-1236.
58. Kim W, Kim SH, Nakashima I, Takai Y, Fujihara K, Leite MI, et al (2012) Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78: 1264-1267.
59. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135: 1834-1849.
60. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79: 1273-1277.
61. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 84: 918-921.
62. Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP, et al (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69: 239-245.
63. Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, Misu T, et al (2013) Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254: 178-182.
64. Lana-Peixoto MA, (2008) Clinical features of neuromyelitis optica in Latin American populations. Mult Scler 14: S19.
65. Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, et al (2012) Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78: 1601-1607.
66. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112.
67. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR, (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477.
68. Levin MH, Bennett JL, Verkman AS, (2013) Optic neuritis in neuromyelitis optica. Prog Retin Eye Res 36: 159-171.
69. Li Y, Xie P, Lv F, Mu J, Li Q, Yang Q, et al (2008) Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 118: 218-225.
70. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125: 1450-1461.
71. Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al (2009) Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 72: 712-717.
72. Mandler RN, Ahmed W, Dencoff JE, (1998) Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51: 1219-1220.
73. Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zephir H, et al (2013) Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 80: 2194-2200.
74. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG, (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70: 2197-2200.
75. Matiello M, Kim HJ, Kim W, Brum DG, Barreira AA, Kingsbury DJ, et al (2010) Familial neuromyelitis optica. Neurology 75: 310-315.
76. Matiello M, Schaefer-Klein J, Brum DG, Atkinson EJ, Kantarci OH, Weinshenker BG, (2010) HLA-DRB11501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. Mult Scler 16: 981-984.
77. Matthews L, Marasco R, Jenkinson M, Kuker W, Luppe S, Leite MI, et al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80: 1330-1337.
78. McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, et al (2008) CNS aquaporin-4 autoimmunity in children. Neurology 71: 93-100.
79. McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, et al (2009) Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39: 87-90.
80. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M, (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69: 1176-1180.
81. Mehta LR, Samuelsson MK, Kleiner AK, Goodman AD, Anolik JH, Looney RJ, Schwid SR, (2008) Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mult Scler 14: 425-427.
82. Merle H, Olindo S, Bonnan M, Donnio A, Richer R, Smadja D, Cabre P, (2007) Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 114: 810-815.
83. Merle H, Olindo S, Donnio A, Richer R, Smadja D, Cabre P, (2008) Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 49: 4412-4417.
84. Min JH, Kim BJ, Lee KH, (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18: 113-115.
85. Minagar A, Sheremata WA, (2000) Treatment of Devic's disease with methotrexate and prednisone. Int J MS Care 2: 43-49.
86. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y, (2005) Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65: 1479-1482.
87. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234.
88. Misu T, Hoftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, et al (2013) Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 125: 815-827.
89. Miyamoto K, Kusunoki S, (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13: 505-508.
90. Miyazawa I, Fujihara K, Itoyama Y, (2001) Neuromyelitis optica(Devic disease) and optic-spinal form multiple sclerosis. No To Shinkei 53: 901-910.
91. Mok CC, To CH, Mak A, Poon WL, (2008) Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 35: 172-174.
92. Monteiro ML, Fernandes DB, Apostolos-Pereira SL, Callegaro D, (2012) Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci 53: 3959-3966.
93. Nakajima H, Hosokawa T, Sugino M, Kimura F, Sugasawa J, Hanafusa T, Takahashi T, (2010) Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol 10: 45.
94. Nakamura M, Miyazawa I, Fujihara K, Nakashima I, Misu T, Watanabe S, et al (2008) Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 255: 163-170.
95. Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, et al (2009) Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15: 695-700.
96. Nakamura M, Nakazawa T, Doi H, Hariya T, Omodaka K, Misu T, et al (2010) Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 248: 1777-1785.
97. Nakashima I, Fujihara K, Sato S, Itoyama Y, (2005) Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol 159: 133-136.
98. Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, et al (2011) Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 18: 997-998.
99. Neto SP, Alvarenga RM, Vasconcelos CC, Alvarenga MP, Pinto LC, Pinto VL, (2013) Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica. Mult Scler 19: 173-178.
100. Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, et al (1999) Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 40: 2520-2527.
101. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76: 1310-1315.
102. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT, (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 81: 109-111.
103. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG, (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63: 390-396.
104. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA, (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63: 964-968.
105. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65: 78-83.
106. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12: 554-562.
107. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gomez JA, et al (2011) Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 76: 1229-1237.
108. Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman E, Balcer LJ, et al (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73: 302-308.
109. Raz N, Vaknin A, Chokron S, Ben-Hur T, Levin N, (2010) Functional MRI as a tool for assessing chiasmal visual defect in a patient with neuromyelitis optica. J Neurol Neurosurg Psychiatry 81: 1174-1175.
110. Romero RS, Gutierrez I, Wang E, Reder AT, Bhatti MT, Bernard JT, Javed A, (2012) Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol 32: 150-153.
111. Sato D, Fujihara K, (2010) Neuromyelitis optica without typical opticospinal phenotype. Mult Scler 16: 1154-1155.
112. Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K, (2012) Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 70: 59-66.
113. Sato DK, Nakashima I, Takahashi T, Misu T, Waters P, Kuroda H, et al (2013) Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 80: 2210-2216.
114. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, Garcia-Layana A, Bejarano B, Villoslada P, (2007) Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 68: 1488-1494.
115. Shimizu Y, Fujihara K, Kubo S, Takahashi T, Misu T, Nakashima I, et al (2011) Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis. Tohoku J Exp Med 223: 211-214.
116. Siritho S, Nakashima I, Takahashi T, Fujihara K, Prayoonwiwat N, (2011) AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology 77: 827-834.
117. Sotirchos ES, Saidha S, Byraiah G, Mealy MA, Ibrahim MA, Sepah YJ, et al (2012) In-vivo identification of a novel retinal pathology in neuromyelitis optica. ECTRIMS. Meeting Abstracts P657. Mult Scler 18: 288.
118. Storoni M, Verbeek MM, Illes Z, Marignier R, Teunissen CE, Grabowska M, et al (2012) Serum GFAP levels in optic neuropathies. J Neurol Sci 317: 117-122.
119. Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT, (2013) Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 33: 123-127.
120. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al (2010) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 25: 83-177.
121. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al (2008) Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 79: 1075-1078.
122. Takai Y, Misu T, Nakashima I, Takahashi T, Itoyama Y, Fujihara K, Aoki M, (2012) Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 79: 1826-1828.
123. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y, (2010) Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216.
124. Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK, Stangel M, (2011) Longitudinal extensive transverse myelitis-it's not all neuromyelitis optica. Nat Rev Neurol 7: 688-698.
125. Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, et al (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58: 383-391.
126. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al (2010) Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16: 1443-1452.
127. Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L, et al (2011) Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Arch Neurol 68: 1557-1561.
128. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, Itoyama Y, (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13: 968-974.
129. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y, (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13: 128-132.
130. Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78: 665-671.
131. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA, (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59: 566-569.
132. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R, (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63: 957-963.
133. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG, (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107-1114.
134. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG, (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489.
135. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG, (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6: 805-815.
136. Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52: 969-972.
137. Yoshida H, Ando A, Sho K, Akioka M, Kawai E, Arai E, et al (2010) Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis. J Ocul Pharmacol 26: 381-385.